ETV4：在恶性肿瘤与肿瘤免疫微环境中的 研究进展——ETS变异转录因子4 (ETV4)在恶性肿瘤发生发展及肿瘤 免疫微环境调控中的研究进展
ETV4: Research Advances in Malignant Tumors and Tumor Immune Microenvironment—Advances in the Role of ETS Variant Transcription Factor 4 (ETV4) in Tumorigenesis, Tumor Progression and Modulation of Tumor Immune Microenvironment
DOI: 10.12677/acm.2026.1641702, PDF,    科研立项经费支持
作者: 孟瑞鹏, 王 亮*：内蒙古医科大学附属鄂尔多斯市中心医院普外科，内蒙古 鄂尔多斯
关键词: ETV4；肿瘤免疫微环境；肿瘤相关巨噬细胞；免疫治疗；ETV4； Tumor Immune Microenvironment； Tumor-Associated Macrophages； Immunotherapy
摘要: ETS变异转录因子4 (E26 transformation-specific variant transcription factor 4, ETV4)是ETS转录因子家族的核心成员，能通过特异性识别靶基因启动子/增强子区的5'-GGA(A/T)-3'保守基序，在转录层面精准调控下游基因的表达。过去十几年里，大量基础与临床研究已经证实，ETV4在绝大多数实体瘤中都存在异常高表达的情况，它不仅能通过调控细胞周期进程、上皮–间质转化、肿瘤干细胞特性等过程，直接驱动肿瘤细胞增殖、侵袭和远处转移；更能通过转录调控趋化因子、细胞因子和免疫检查点分子网络，重塑肿瘤免疫微环境(Tumor Immune Microenvironment, TME)，推动免疫抑制表型的形成，是肿瘤免疫逃逸和治疗耐药的关键上游调控因子。本文系统梳理了ETV4的分子生物学特征、在恶性肿瘤中的表达谱特点和临床病理学意义，重点阐述了它调控肿瘤细胞自主性生物学行为与TME重塑的核心分子机制，同时总结了靶向ETV4的肿瘤治疗策略最新研究进展，希望能为该领域后续的基础研究和临床转化提供全面的理论参考。
Abstract: ETS variant transcription factor 4 (ETV4) is a core member of the ETS transcription factor family, which can precisely regulate the expression of downstream genes at the transcriptional level by specifically recognizing the 5'-GGA(A/T)-3' conserved motif in the promoter/enhancer region of target genes. Over the past decade, a large number of basic and clinical studies have confirmed that ETV4 is abnormally highly expressed in most solid tumors. It can not only directly drive the proliferation, invasion and distant metastasis of tumor cells by regulating cell cycle progression, epithelial-mesenchymal transition, cancer stem cell characteristics and other processes, but also reshape the tumor immune microenvironment (TME) through transcriptional regulation of chemokines, cytokines and immune checkpoint molecular networks, promoting the formation of immunosuppressive phenotype. It is a key upstream regulatory factor of tumor immune escape and therapeutic drug resistance. This paper systematically sorts out the molecular biological characteristics of ETV4, its expression profile characteristics and clinicopathological significance in malignant tumors, focuses on the core molecular mechanism of it regulating tumor cell autonomous biological behavior and TME remodeling, and summarizes the latest research progress of ETV4-targeted tumor therapy strategies, hoping to provide a comprehensive theoretical reference for the subsequent basic research and clinical transformation in this field.
文章引用：孟瑞鹏, 王亮. ETV4：在恶性肿瘤与肿瘤免疫微环境中的 研究进展——ETS变异转录因子4 (ETV4)在恶性肿瘤发生发展及肿瘤 免疫微环境调控中的研究进展[J]. 临床医学进展, 2026, 16(4): 4337-4349. https://doi.org/10.12677/acm.2026.1641702

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] André, T., Shiu, K., Kim, T.W., Jensen, B.V., Jensen, L.H., Punt, C., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. New England Journal of Medicine, 383, 2207-2218. [Google Scholar] [CrossRef] [PubMed]
[3] Espinoza, M., Rojas‐Vallejos, J., Rodríguez, N., Guerrero, G., López, M., Aranguiz, N., et al. (2025) Real‐World Data on Inotuzumab Ozogamicin for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: A Grelal‐Chile Study. Cancer Medicine, 14, e71230. [Google Scholar] [CrossRef] 
[4] Kundu, M., Butti, R., Panda, V.K., Malhotra, D., Das, S., Mitra, T., et al. (2024) Modulation of the Tumor Microenvironment and Mechanism of Immunotherapy-Based Drug Resistance in Breast Cancer. Molecular Cancer, 23, Article No. 92. [Google Scholar] [CrossRef] [PubMed]
[5] Niu, X., You, Q., Hou, K., Tian, Y., Wei, P., Zhu, Y., et al. (2025) Autophagy in Cancer Development, Immune Evasion, and Drug Resistance. Drug Resistance Updates, 78, Article ID: 101170. [Google Scholar] [CrossRef] [PubMed]
[6] Komohara, Y., Fujiwara, Y., Ohnishi, K. and Takeya, M. (2016) Tumor-Associated Macrophages: Potential Therapeutic Targets for Anti-Cancer Therapy. Advanced Drug Delivery Reviews, 99, 180-185. [Google Scholar] [CrossRef] [PubMed]
[7] Zhu, Y., Zhou, Z., Du, X., Lin, X., Liang, Z., Chen, S., et al. (2025) Cancer Cell-Derived Arginine Fuels Polyamine Biosynthesis in Tumor-Associated Macrophages to Promote Immune Evasion. Cancer Cell, 43, 1045-1060.e7. [Google Scholar] [CrossRef] [PubMed]
[8] Oikawa, T. and Yamada, T. (2003) Molecular Biology of the Ets Family of Transcription Factors. Gene, 303, 11-34. [Google Scholar] [CrossRef] [PubMed]
[9] Shindoh, M., Higashino, F. and Kohgo, T. (2004) E1AF, an Ets-Oncogene Family Transcription Factor. Cancer Letters, 216, 1-8. [Google Scholar] [CrossRef] [PubMed]
[10] Lee, S.H., Ahn, J.W., Choi, W., Kim, J., Hwang, J.Y., Kim, J., et al. (2025) Transcription Factor Networks Drive Tumor Progression and Immune Microenvironment Remodeling in Hepatocellular Carcinoma. Cancers, 17, Article 3787. [Google Scholar] [CrossRef] 
[11] Zhang, Q., Liu, S., Wang, H., Xiao, K., Lu, J., Chen, S., et al. (2023) ETV4 Mediated Tumor‐Associated Neutrophil Infiltration Facilitates Lymphangiogenesis and Lymphatic Metastasis of Bladder Cancer. Advanced Science, 10, e2205613. [Google Scholar] [CrossRef] [PubMed]
[12] Coutte, L., Monté, D., Baert, J. and de Launoit, Y. (1999) Genomic Organization of the Human e1af Gene, a Member of Ets Transcription Factors. Gene, 240, 201-207. [Google Scholar] [CrossRef] [PubMed]
[13] Esaki, S., Evich, M.G., Erlitzki, N., Germann, M.W. and Poon, G.M.K. (2017) Multiple DNA-Binding Modes for the ETS Family Transcription Factor PU.1. Journal of Biological Chemistry, 292, 16044-16054. [Google Scholar] [CrossRef] [PubMed]
[14] Currie, S.L., Doane, J.J., Evans, K.S., Bhachech, N., Madison, B.J., Lau, D.K.W., et al. (2017) ETV4 and AP1 Transcription Factors Form Multivalent Interactions with Three Sites on the MED25 Activator-Interacting Domain. Journal of Molecular Biology, 429, 2975-2995. [Google Scholar] [CrossRef] [PubMed]
[15] Wang, Y., Wang, Z., Chen, J., Cai, L., Luo, X. and Wu, N. (2025) ETV4 Promotes Ovarian Cancer Growth by Regulating Mitochondrial Function through Mfn2 Ubiquitination Mediated by the E3 Ubiquitin Ligase MARCH9. Cell Biology and Toxicology, 41, Article No. 141. [Google Scholar] [CrossRef] 
[16] Currie, S.L., Lau, D.K.W., Doane, J.J., Whitby, F.G., Okon, M., McIntosh, L.P., et al. (2017) Structured and Disordered Regions Cooperatively Mediate DNA-Binding Autoinhibition of ETS Factors ETV1, ETV4 and ETV5. Nucleic Acids Research, 45, 2223-2241. [Google Scholar] [CrossRef] [PubMed]
[17] Fung, T.M., Ng, K.Y., Tong, M., Chen, J., Chai, S., Chan, K., et al. (2016) Neuropilin‐2 Promotes Tumourigenicity and Metastasis in Oesophageal Squamous Cell Carcinoma through ERK-MAPK-ETV4-MMP-E‐Cadherin Deregulation. The Journal of Pathology, 239, 309-319. [Google Scholar] [CrossRef] [PubMed]
[18] Xie, M., Lin, Z., Ji, X., Luo, X., Zhang, Z., Sun, M., et al. (2023) FGF19/FGFR4-Mediated Elevation of ETV4 Facilitates Hepatocellular Carcinoma Metastasis by Upregulating PD-L1 and CCL2. Journal of Hepatology, 79, 109-125. [Google Scholar] [CrossRef] [PubMed]
[19] Zhang, H., Jiang, R., Zhu, J., Sun, K., Huang, Y., Zhou, H., et al. (2024) PI3K/Akt/mTOR Signaling Pathway: An Important Driver and Therapeutic Target in Triple-Negative Breast Cancer. Breast Cancer, 31, 539-551. [Google Scholar] [CrossRef] [PubMed]
[20] Cai, R., Tressler, C.M., Cheng, M., Sonkar, K., Tan, Z., Paidi, S.K., et al. (2023) Primary Breast Tumor Induced Extracellular Matrix Remodeling in Premetastatic Lungs. Scientific Reports, 13, Article No. 18566. [Google Scholar] [CrossRef] [PubMed]
[21] Zhu, T., Wei, T., Yang, M., Xu, J., Jiang, H., He, W., et al. (2026) ETV4-Mediated PD-L1 Upregulation Promotes Immune Evasion and Predicts Poor Immunotherapy Response in Melanoma. Oncology Research, 34, 1-10. [Google Scholar] [CrossRef] 
[22] Guan, L., Zeng, R., Chen, Y., He, G., Yao, W., Liu, Z., et al. (2024) Pan-Cancer Analysis of the Potential of PEA3 Subfamily Genes as Tumor Markers. Scientific Reports, 14, Article No. 31518. [Google Scholar] [CrossRef] [PubMed]
[23] Yang, Q., Zhong, S., He, L., Jia, X., Tang, H., Cheng, S., et al. (2019) PBK Overexpression Promotes Metastasis of Hepatocellular Carcinoma via Activating ETV4-uPAR Signaling Pathway. Cancer Letters, 452, 90-102. [Google Scholar] [CrossRef] [PubMed]
[24] Mosaad, H., Ahmed, M.M., Elaidy, M.M., Elfarargy, O.M., Abdelwahab, M.M. and Abdelnour, H.M. (2023) Down-regulated miRNA 29-b as a Diagnostic Marker in Colorectal Cancer and Its Correlation with ETV4 and Cyclin D1 Immunohistochemical Expression. Cancer Biomarkers, 37, 179-189. [Google Scholar] [CrossRef] [PubMed]
[25] Cai, L.S., Chen, Q.X., Fang, S.Y., Lian, M.Q., Lian, M.J. and Cai, M.Z. (2020) ETV4 Promotes the Progression of Gastric Cancer through Regulating KDM5D. European Review for Medical and Pharmacological Sciences, 24, 2442-2451.
[26] Hashimoto, S., Furukawa, S., Hashimoto, A., Tsutaho, A., Fukao, A., Sakamura, Y., et al. (2019) ARF6 and AMAP1 Are Major Targets of KRAS and TP53 Mutations to Promote Invasion, PD-L1 Dynamics, and Immune Evasion of Pancreatic Cancer. Proceedings of the National Academy of Sciences of the United States of America, 116, 17450-17459. [Google Scholar] [CrossRef] [PubMed]
[27] Tian, T., Lu, Y., Lin, J., Chen, M., Qiu, H., Zhu, W., et al. (2022) CPT1A Promotes Anoikis Resistance in Esophageal Squamous Cell Carcinoma via Redox Homeostasis. Redox Biology, 58, Article ID: 102544. [Google Scholar] [CrossRef] [PubMed]
[28] Cosi, I., Moccia, A., Nannelli, C., Rosini, D., Iozzo, M., Sica, M., et al. (2025) ETV4 and ETV1-Mediated Downregulation of the Secretory Leukocyte Protease Inhibitor Contributes to the Indolent Phenotype of Early-Stage Prostate Cancer. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1871, Article ID: 167975. [Google Scholar] [CrossRef] [PubMed]
[29] Zhu, T., Zheng, J., Zhuo, W., Pan, P., Li, M., Zhang, W., et al. (2021) ETV4 Promotes Breast Cancer Cell Stemness by Activating Glycolysis and CXCR4-Mediated Sonic Hedgehog Signaling. Cell Death Discovery, 7, Article No. 126. [Google Scholar] [CrossRef] [PubMed]
[30] Rodriguez, A.C., Vahrenkamp, J.M., Berrett, K.C., Clark, K.A., Guillen, K.P., Scherer, S.D., et al. (2020) ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells. Cancer Research, 80, 1234-1245. [Google Scholar] [CrossRef] [PubMed]
[31] Zhang, J., Wang, Y., Cao, S., Xie, S.M., Liu, B., Li, Y., et al. (2025) Topoisomerase I Inhibition in ETV4‐Overexpressed Non‐Small Cell Lung Cancer Promotes Replication and Transcription Mediated R‐Loop Accumulation and DNA Damage. Advanced Science, 12, e09307. [Google Scholar] [CrossRef] [PubMed]
[32] Tang, Y., Xie, W., Hu, T., Huang, C., Yin, W., Wei, S., et al. (2025) Identification of ETV4 as a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Head and Neck Squamous Cell Carcinoma. Scientific Reports, 15, Article No. 7044. [Google Scholar] [CrossRef] [PubMed]
[33] Hung, Y.P., Fletcher, C.D. and Hornick, J.L. (2016) Evaluation of ETV4 and WT1 Expression in CIC-Rearranged Sarcomas and Histologic Mimics. Modern Pathology, 29, 1324-1334. [Google Scholar] [CrossRef] [PubMed]
[34] Wouters, J., Kalender-Atak, Z., Minnoye, L., Spanier, K.I., De Waegeneer, M., Bravo González-Blas, C., et al. (2020) Robust Gene Expression Programs Underlie Recurrent Cell States and Phenotype Switching in Melanoma. Nature Cell Biology, 22, 986-998. [Google Scholar] [CrossRef] [PubMed]
[35] Zong, W., Wang, Y. and Xu, B. (2026) ETV4 Transcriptionally Activates STAT6 to Inhibit Ferroptosis and Promote Immune Escape in Thyroid Cancer. Endocrine Research. [Google Scholar] [CrossRef] 
[36] Lu, Z., Williamson, S.R., Carskadon, S., Arachchige, P.D., Dhamdhere, G., Schultz, D.S., et al. (2010) Clonal Evaluation of Early Onset Prostate Cancer by Expression Profiling of ERG, SPINK1, ETV1, and ETV4 on Whole‐Mount Radical Prostatectomy Tissue. The Prostate, 80, 38-50. [Google Scholar] [CrossRef] [PubMed]
[37] Zheng, C., Liu, M., Ge, Y., Qian, Y. and Fan, H. (2022) HBX Increases Chromatin Accessibility and ETV4 Expression to Regulate Dishevelled-2 and Promote HCC Progression. Cell Death & Disease, 13, Article No. 116. [Google Scholar] [CrossRef] [PubMed]
[38] Dai, M.J., Chen, L.L., Zheng, Y.B., Chen, W., Tao, Z.H., Weng, Z.L., et al. (2008) [Frequency and Transcript Variant Analysis of Gene Fusions between TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer]. Chinese Journal of Medical Genetic, 88, 669-673.
[39] Lobo, J., He, H., Ahmed, R., Zein-Sabatto, B., Winokur, T., Wei, S., et al. (2025) Primary Ewing Sarcoma of the Kidney: Clinicopathologic and Molecular Study of 24 Patients Including a Rare EWSR1::ETV4 Fusion. American Journal of Surgical Pathology, 49, 1078-1089. [Google Scholar] [CrossRef] [PubMed]
[40] Mahajan, M., Dhabalia, S., Dash, T., Sarkar, A. and Mondal, S. (2025) A Comprehensive Multi-Omics Study Reveals Potential Prognostic and Diagnostic Biomarkers for Colorectal Cancer. International Journal of Biological Macromolecules, 303, Article ID: 140443. [Google Scholar] [CrossRef] [PubMed]
[41] Wang, H., Dai, Y. and Wang, F. (2024) Etv4mediated Transcriptional Activation of SLC12A5 Exacerbates Ferroptosis Resistance and Glucose Metabolism Reprogramming in Breast Cancer Cells. Molecular Medicine Reports, 30, Article No. 217. [Google Scholar] [CrossRef] [PubMed]
[42] Tyagi, N., Deshmukh, S.K., Srivastava, S.K., Azim, S., Ahmad, A., AL-Ghadhban, A., et al. (2018) ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1. Molecular Cancer Research, 16, 187-196. [Google Scholar] [CrossRef] [PubMed]
[43] Cosi, I., Pellecchia, A., De Lorenzo, E., Torre, E., Sica, M., Nesi, G., et al. (2020) ETV4 Promotes Late Development of Prostatic Intraepithelial Neoplasia and Cell Proliferation through Direct and P53-Mediated Downregulation of P21. Journal of Hematology & Oncology, 13, Article No. 112. [Google Scholar] [CrossRef] [PubMed]
[44] Su, H., Shu, S., Tang, W., Zheng, C., Zhao, L. and Fan, H. (2023) ETV4 Facilitates Angiogenesis in Hepatocellular Carcinoma by Upregulating MMP14 Expression. Biochemical and Biophysical Research Communications, 684, Article ID: 149137. [Google Scholar] [CrossRef] [PubMed]
[45] Liu, D., Wei, Y., Zhou, F., Ge, Y., Xu, J., Chen, H., et al. (2008) E1AF Promotes Mithramycin A-Induced Huh-7 Cell Apoptosis Depending on Its DNA-Binding Domain. Archives of Biochemistry and Biophysics, 477, 20-26. [Google Scholar] [CrossRef] [PubMed]
[46] Habelhah, H., Okada, F., Kobayashi, M., Nakai, K., Choi, S., Hamada, J., et al. (1999) Increased E1AF Expression in Mouse Fibrosarcoma Promotes Metastasis through Induction of MT1-MMP Expression. Oncogene, 18, 1771-1776. [Google Scholar] [CrossRef] [PubMed]
[47] Chen, Y., Sumardika, I.W., Tomonobu, N., Kinoshita, R., Inoue, Y., Iioka, H., et al. (2019) Critical Role of the MCAM-ETV4 Axis Triggered by Extracellular S100A8/A9 in Breast Cancer Aggressiveness. Neoplasia, 21, 627-640. [Google Scholar] [CrossRef] [PubMed]
[48] Hao, L., Pang, K., Pang, H., Zhang, J., Zhang, Z., He, H., et al. (2020) Knockdown of P3H4 Inhibits Proliferation and Invasion of Bladder Cancer. Aging, 12, 2156-2168. [Google Scholar] [CrossRef] [PubMed]
[49] Boutilier, A.J. and Elsawa, S.F. (2021) Macrophage Polarization States in the Tumor Microenvironment. International Journal of Molecular Sciences, 22, Article 6995. [Google Scholar] [CrossRef] [PubMed]
[50] Piao, H., Fu, L., Wang, Y., Liu, Y., Wang, Y., Meng, X., et al. (2022) A Positive Feedback Loop between Gastric Cancer Cells and Tumor-Associated Macrophage Induces Malignancy Progression. Journal of Experimental & Clinical Cancer Research, 41, Article No. 174. [Google Scholar] [CrossRef] [PubMed]
[51] Henriques, A., Salvany-Celades, M., Nieto, P., Palomo-Ponce, S., Sevillano, M., Hernando-Momblona, X., et al. (2025) TGF-β Builds a Dual Immune Barrier in Colorectal Cancer by Impairing T Cell Recruitment and Instructing Immunosuppressive SPP1+ Macrophages. Nature Genetics, 57, 3050-3065. [Google Scholar] [CrossRef] 
[52] Deng, G., Wang, P., Su, R., Sun, X., Wu, Z., Huang, Z., et al. (2024) SPI1+CD68+ Macrophages as a Biomarker for Gastric Cancer Metastasis: A Rationale for Combined Antiangiogenic and Immunotherapy Strategies. Journal for ImmunoTherapy of Cancer, 12, e009983. [Google Scholar] [CrossRef] [PubMed]
[53] Shen, X., Zhou, C., Feng, H., Li, J., Xia, T., Cheng, X., et al. (2022) ETV1 Positively Correlated with Immune Infiltration and Poor Clinical Prognosis in Colorectal Cancer. Frontiers in Immunology, 13, Article 939806. [Google Scholar] [CrossRef] [PubMed]
[54] Tun, K.M., Kitkumthorn, N., Bumalee, D., Arayapisit, T. and Lapthanasupkul, P. (2023) Differential Expression of PEA3 in Odontogenic Cysts and Tumors. Journal of Oral Pathology & Medicine, 52, 777-785. [Google Scholar] [CrossRef] [PubMed]
[55] Zhao, Y., Zhang, Q., Tu, K., Chen, Y., Peng, Y., Ni, Y., et al. (2022) Single-Cell Transcriptomics of Immune Cells Reveal Diversity and Exhaustion Signatures in Non-Small-Cell Lung Cancer. Frontiers in Immunology, 13, Article 854724. [Google Scholar] [CrossRef] [PubMed]
[56] Kalina, J.L., Neilson, D.S., Lin, Y., Hamilton, P.T., Comber, A.P., Loy, E.M.H., et al. (2017) Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer. Clinical Cancer Research, 23, 7596-7607. [Google Scholar] [CrossRef] [PubMed]
[57] Xu, X., Wang, B., Liu, Y., Jing, T., Xu, G., Zhang, L., et al. (2022) ETV4 Potentiates Nuclear YAP Retention and Activities to Enhance the Progression of Hepatocellular Carcinoma. Cancer Letters, 537, Article ID: 215640. [Google Scholar] [CrossRef] [PubMed]
[58] Li, M., Ni, Q. and Yu, S. (2023) Integration of Single-Cell Transcriptomics and Epigenetic Analysis Reveals Enhancer-Controlled TIMP1 as a Regulator of Ferroptosis in Colorectal Cancer. Genes & Genomics, 46, 121-133. [Google Scholar] [CrossRef] [PubMed]
[59] Park, J.S., Kang, M., Kim, H.B., Hong, H., Lee, J., Song, Y., et al. (2024) The Capicua-Ataxin-1-Like Complex Regulates Notch-Driven Marginal Zone B Cell Development and Sepsis Progression. Nature Communications, 15, Article No. 10579. [Google Scholar] [CrossRef] [PubMed]
[60] Yang, P., He, S., Ye, L. and Weng, H. (2024) Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma. International Archives of Allergy and Immunology, 185, 910-920. [Google Scholar] [CrossRef] [PubMed]
[61] Jia, D., Wang, P., Zheng, S., Lei, Z., Xu, W., Wang, Y., et al. (2025) KRAS Mutations Promote PD-L1-Mediated Immune Escape by ETV4 in Lung Adenocarcinoma. Translational Oncology, 61, Article ID: 102525. [Google Scholar] [CrossRef] 
[62] Zhang, H., Gao, M., Gao, Z., Yao, L., Sun, H., Wang, H., et al. (2025) Identification and Validation of SUN Modification-Related Anti-PD-1 Immunotherapy-Resistance Signatures to Predict Prognosis and Immune Microenvironment Status in Glioblastoma. BMC Cancer, 26, Article No. 7. [Google Scholar] [CrossRef] 
[63] Huang, Y., He, J., Chen, N., Du, X. and Peng, J. (2025) ETV4 Promotes the Growth, Metastasis, Glycolysis, and Oxaliplatin Resistance of Colorectal Cancer by Transcription Activation-Mediated SLC38A5 Upregulation. Pathology—Research and Practice, 271, Article ID: 156033. [Google Scholar] [CrossRef] [PubMed]
[64] Babl, N., Voll, F., Martowicz, A., Bruss, C., Maddaloni, M., Schmidl, C., et al. (2026) Lactic Acid Promotes an MDSC-Like Phenotype via Hif1α Stabilization with Impact on Prognosis in Renal Cell Carcinoma. Cancer Letters, 639, Article ID: 218209. [Google Scholar] [CrossRef] 
[65] He, R., Wei, Y., Peng, Z., Yang, J., Zhou, Z., Li, A., et al. (2024) Α-Ketoglutarate Alleviates Osteoarthritis by Inhibiting Ferroptosis via the ETV4/SLC7A11/GPX4 Signaling Pathway. Cellular & Molecular Biology Letters, 29, Article No. 88. [Google Scholar] [CrossRef] [PubMed]

为你推荐